Natural history of B-cell dysfunction in spontaneously diabetic Chinese hamsters

1994 ◽  
Vol 24 (3) ◽  
pp. 131-142 ◽  
Author(s):  
Katsumi Nakajima ◽  
Akizuki Morikawa ◽  
Isao Makino
Keyword(s):  
Natural History ◽  
B Cell ◽  
Cell Dysfunction ◽  
Chinese Hamsters ◽  
History Of ◽  
Diabetic Chinese Hamsters

Antibody Therapy in Aggressive Lymphomas

Hematology ◽  
2007 ◽  
Vol 2007 (1) ◽  
pp. 257-264 ◽  
Author(s):  
Thomas M. Habermann
Keyword(s):  
Monoclonal Antibody ◽  
T Cell ◽  
Natural History ◽  
B Cell ◽  
Antibody Therapy ◽  
Lymphoproliferative Disorders ◽  
Monoclonal Antibody Therapy ◽  
Aggressive Lymphomas ◽  
History Of ◽  
Anti Cd20

AbstractThe aggressive lymphomas are potentially curable. The natural history of certain aggressive lymphomas has been altered by monoclonal antibody therapy. Targeted monoclonal antibody therapy to the CD20 antigen has altered the outcome of patients with diffuse large B-cell lymphoma in patients of all ages. Anti-CD20–based radioimmunoconjugates are being evaluated as radioimmunotherapy approaches in patients who have relapsed and in stem cell transplant settings. Antibody-directed therapy to the B-cell–specific antigen CD22 are ongoing. New approaches include different CD20 antibodies and an antibody to the CD40 antigen, which is a member of the tumor necrosis factor (TNF) receptor family, which is expressed on B-cells. Antibody therapy has been incorporated into CHOP (cyclophosphamide, adriamycin, vincristine, prednisone) therapy and other regimens such as EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) and HyperCVAD (cyclophosphamide, vincristine, adriamycin, dexamethasone). Single-agent anti-CD20 therapy is active in the post-transplantation lymphoproliferative disorders. T-cell antibodies are under evaluation in a number of T-cell lymphoproliferative disorders. Targeted therapy has changed the natural history of a number of aggressive non-Hodgkin lymphomas. This review will describe the contributions of antibody therapies to the treatment of these diseases.

scholarly journals C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas

2020 ◽  
Vol 4 (22) ◽  
pp. 5858-5862
Author(s):  
Caron A. Jacobson ◽  
Marcela V. Maus
Keyword(s):  
T Cells ◽  
Natural History ◽  
B Cell ◽  
Lymphoblastic Leukemia ◽  
Cellular Immunotherapy ◽  
Car T Cells ◽  
Early Results ◽  
Car T ◽  
Mantle Cell ◽  
History Of

Abstract Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 has transformed the natural history of relapsed and refractory B-cell acute lymphoblastic leukemia and aggressive B-cell non-Hodgkin lymphoma. Based on these results, CD19 CAR T cells have since been tested in largely incurable lymphomas, including mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma, with promising early results that raise the question of whether this cellular immunotherapy could have curative potential and change the natural history of these diseases. This article reviews these results and this hypothesis.

Natural History of  -Cell Dysfunction in NIDDM

Diabetes Care ◽  
1990 ◽  
Vol 13 (9) ◽  
pp. 992-1010 ◽  
Author(s):  
J. L. Leahy
Keyword(s):  
Natural History ◽  
Cell Dysfunction ◽  
History Of

Prevalence and natural history of monoclonal and polyclonal B-cell lymphocytosis in a residential adult population

2007 ◽  
Vol 72B (5) ◽  
pp. 344-353 ◽  
Author(s):  
Youn K. Shim ◽  
Robert F. Vogt ◽  
Dan Middleton ◽  
Fatima Abbasi ◽  
Barbara Slade ◽  
...  
Keyword(s):  
Natural History ◽  
B Cell ◽  
Adult Population ◽  
History Of

scholarly journals Brief Report: Natural History of Individuals With Clinically Recognized Monoclonal B-Cell Lymphocytosis Compared With Patients With Rai 0 Chronic Lymphocytic Leukemia

2009 ◽  
Vol 27 (24) ◽  
pp. 3959-3963 ◽  
Author(s):  
Tait D. Shanafelt ◽  
Neil E. Kay ◽  
Kari G. Rabe ◽  
Timothy G. Call ◽  
Clive S. Zent ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Natural History ◽  
B Cell ◽  
Cell Count ◽  
Medical Records ◽  
Absolute Lymphocyte Count ◽  
Continuous Variable ◽  
Lymphocytic Leukemia ◽  
Cell Counts ◽  
History Of

Purpose The diagnosis of monoclonal B-cell lymphocytosis (MBL) is used to characterize patients with a circulating population of clonal B cells, a total B-cell count of less than 5 × 109/L, and no other features of a B-cell lymphoproliferative disorder including lymphadenopathy/organomegaly. The natural history of clinically identified MBL is unclear. The goal of this study was to explore the outcome of patients with MBL relative to that of individuals with Rai stage 0 chronic lymphocytic leukemia (CLL). Patients and Methods We used hematopathology records to identify a cohort of 631 patients with newly diagnosed MBL or Rai stage 0 CLL. Within this cohort, 302 patients had MBL (B-cell counts of 0.02 to 4.99 × 109/L); 94 patients had Rai stage 0 CLL with an absolute lymphocyte count (ALC) ≤ 10 × 109/L; and 219 patients had Rai stage 0 CLL with an ALC more than 10 × 109/L. Data on clinical outcome were abstracted from medical records. Results The percentage of MBL patients free of treatment at 1, 2, and 5 years was 99%, 98%, and 93%, respectively. B-cell count as a continuous variable (hazard ratio [HR] = 2.9, P = .04) and CD38 status (HR = 10.8, P = .006) predicted time to treatment (TTT) among MBL patients. The likelihood of treatment for MBL patients was lower (HR = 0.32, P = .04) than that of both Rai stage 0 CLL patients with an ALC less than 10 × 109/L (n = 94) and Rai stage 0 CLL patients with an ALC more than 10 × 109/L (n = 219; P = .0003). Conclusion Individuals with MBL identified in clinical practice have a low risk for progression at 5 years. Because B-cell count seems to relate to TTT as a continuous variable, additional studies are needed to determine what B-cell count should be used to distinguish between MBL and CLL.

scholarly journals Natural History of Monoclonal B-cell Lymphocytosis (MBL) Among Relatives in Chronic Lymphocytic Leukemia (CLL) Families

Blood ◽  
2020 ◽  
Author(s):  
Susan L. Slager ◽  
Mark C Lanasa ◽  
Gerald e Marti ◽  
Sara J Achenbach ◽  
Nicola J Camp ◽  
...  
Keyword(s):  
General Population ◽  
Natural History ◽  
B Cell ◽  
Cumulative Incidence ◽  
Lymphocytic Leukemia ◽  
High Count ◽  
Rate Of Progression ◽  
History Of ◽  
Age And Sex

CLL has one of the highest familial-risks among cancers. MBL, the precursor to CLL, has a higher prevalence (13-18%) in families with two or more members with CLL compared to the general population (5-12%). Although, the rate of progression to CLL for high-count MBLs (clonal B-cell count³500/µL) is ~1-5%/year, no low-count MBLs has been reported to progress to date. We report the incidence and natural history of MBL in relatives from CLL families. In 310 CLL families, we screened 1045 relatives for MBL using highly-sensitive flow cytometry and prospectively followed 449 of them. MBL incidence was directly age- and sex-adjusted to the 2010 United States population. CLL cumulative incidence was estimated using Kaplan-Meier survival curves. At baseline, the prevalence of MBL was 22% (235/1045 relatives). After a median follow-up of 8.1 years among 449 relatives, twelve individuals progressed to CLL with a 5-year cumulative incidence of 1.8%. When considering just the 139 relatives with low-count MBL, the 5-year cumulative incidence increased to 5.7%. Finally, 264 had no MBL at baseline of whom 60 individuals subsequently developed MBL (two high-count and 58 low-count MBLs) with an age- and sex-adjusted incidence of 3.5% after a median of 6 years of follow-up. In a screening cohort of relatives from CLL families, we reported progression from normal to low-count MBL to high-count MBL to CLL, demonstrating that low-count MBL precedes progression to CLL. We estimated a 1.1% annual rate of progression from low-count MBL, which is in excess to that in the general population.

Sign in / Sign up

Export Citation Format

Share Document